SGHERZA, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 394
EU - Europa 188
AS - Asia 75
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 660
Nazione #
US - Stati Uniti d'America 393
IT - Italia 100
SE - Svezia 48
CN - Cina 26
HK - Hong Kong 19
SG - Singapore 14
GB - Regno Unito 10
BE - Belgio 6
DE - Germania 6
IE - Irlanda 5
RU - Federazione Russa 5
FR - Francia 3
IN - India 3
JP - Giappone 3
TR - Turchia 3
TW - Taiwan 3
CZ - Repubblica Ceca 2
EU - Europa 2
TH - Thailandia 2
BR - Brasile 1
CA - Canada 1
FI - Finlandia 1
KR - Corea 1
NL - Olanda 1
PH - Filippine 1
RO - Romania 1
Totale 660
Città #
Fairfield 46
Chandler 43
Nyköping 42
Woodbridge 29
Ashburn 26
Seattle 26
Houston 21
Wilmington 17
Ann Arbor 14
Cambridge 14
New York 14
Bari 13
Singapore 12
Lawrence 11
Inglewood 10
Des Moines 9
Roxbury 8
Gesualdo 7
Brussels 6
Santa Clara 6
Imbersago 5
San Diego 5
Alcamo 4
Bitonto 4
Dublin 4
Los Angeles 4
Modugno 4
Princeton 4
Avellino 3
Beijing 3
Chiswick 3
Florence 3
Guangzhou 3
Istanbul 3
Paris 3
Verona 3
Bengaluru 2
Bisceglie 2
Brno 2
Chiang Mai 2
Dearborn 2
Edinburgh 2
Fragagnano 2
Hefei 2
Itri 2
Jacksonville 2
London 2
Milan 2
Moscow 2
Nagano 2
Nanjing 2
Norwalk 2
Palermo 2
Rome 2
Taipei 2
Washington 2
Anaheim 1
Boardman 1
Bologna 1
Bucharest 1
Bunker Hill 1
Casoria 1
Florianópolis 1
Frankfurt am Main 1
Fuzhou 1
Groningen 1
Hebei 1
Hong Kong 1
Jiaxing 1
Kunming 1
Manila 1
Marcianise 1
Montreal 1
Munich 1
Naples 1
New Taipei 1
Noicattaro 1
Padova 1
Pavia 1
Queens 1
Redwood City 1
Shanghai 1
Siena 1
Taizhou 1
Triggiano 1
Valenzano 1
Wuhan 1
Yiwu 1
Zhengzhou 1
Totale 505
Nome #
null 96
Challenges and opportunities of MicroRNAs in lymphomas 85
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 79
null 68
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 67
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 49
What Is New in the Treatment of Smoldering Multiple Myeloma? 33
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 32
null 28
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 26
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 25
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 24
Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: “Chance or Causality?” 21
Implications of interleukin-6 (Il-6)-blockade for severe covid-19 infection in patients with multiple myeloma 16
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 14
Dasatinib first-line: Multicentric Italian experience outside clinical trials 14
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 14
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 13
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials 6
Serological response following BNT162b2 anti-SARS-COV-2 mRNA vaccination in hematopoietic stem cell transplantation patients 3
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 2
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 2
Totale 717
Categoria #
all - tutte 4.785
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.785


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202086 0 0 3 6 10 7 13 13 12 8 7 7
2020/202162 7 3 5 3 4 13 3 6 6 4 7 1
2021/2022120 21 8 0 8 6 9 14 5 5 7 21 16
2022/2023139 14 29 14 7 5 16 4 24 20 0 6 0
2023/2024187 26 31 26 8 15 28 29 5 0 0 6 13
2024/202558 23 7 28 0 0 0 0 0 0 0 0 0
Totale 717